Mouse models of cystic fibrosis: Phenotypic analysis and research applications

Journal of Cystic Fibrosis

Volumn 10, Issue SUPPL. 2, 2011, Pages

  Wilke, Martina ^a   Buijs Offerman, Ruvalic M ^a   Aarbiou, Jamil ^a   Colledge, William H ^b   Sheppard, David N ^c   Touqui, Lhousseine ^d   Bot, Alice ^a   Jorna, Huub ^a   De Jonge, Hugo R ^a   Scholte, Bob J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d INSTITUT PASTEUR   (France)

Author keywords

Animal models; CFTR mice; Cystic fibrosis; F508del CFTR; Intestinal disease; Lung disease

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; AZITHROMYCIN; BICARBONATE; CERAMIDE; CHOLIC ACID; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCOSAHEXAENOIC ACID; EPITHELIAL SODIUM CHANNEL; FENRETINIDE; FORSKOLIN; GENISTEIN; GLAFENINE; GLYCOSYLATED PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROGOL; MIGLUSTAT; PROTEIN; PYROPHOSPHATE; SILDENAFIL; TOLL LIKE RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VARDENAFIL; VITAMIN D;

AIRWAY REMODELING; AMINO ACID SEQUENCE; ANIMAL HUSBANDRY; ARTICLE; BILE; BILE DUCT DISEASE; BODY WEIGHT; BONE DENSITY; BREEDING; BRONCHIOLE; CALCIUM SIGNALING; CARTILAGE; CECUM; CHANNEL GATING; CHRONIC INFLAMMATION; CLARA CELL; COLON; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MOUSE; CYTOKINE PRODUCTION; DEPOLARIZATION; DIET THERAPY; DUODENUM; ELECTROPHYSIOLOGY; ENTEROPATHY; EPITHELIUM CELL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GALLBLADDER; GALLBLADDER EPITHELIUM; GAUCHER DISEASE; GENE; GENE DELETION; GENE INACTIVATION; GENE MAPPING; GENE MUTATION; GENETIC DRIFT; GENETIC TRANSCRIPTION; GENOTYPE; GOBLET CELL; HETEROZYGOSITY; HOMOZYGOSITY; HYPERPLASIA; ILEUM; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; INTESTINE CELL; INTESTINE OBSTRUCTION; INTRACELLULAR SIGNALING; ION TRANSPORT; JEJUNUM; KIDNEY; LIPID METABOLISM; LIVER; LIVER DISEASE; LUNG; LUNG DISEASE; MALE INFERTILITY; MORTALITY; MOUSE MUTANT; MUCOCILIARY CLEARANCE; MUCUS; MUSCLE STRENGTH; MYOTUBE; NONHUMAN; OLFACTORY EPITHELIUM; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; PANCREAS; PATHOPHYSIOLOGY; PHENOTYPE; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT DISEASE; SALIVARY GLAND; SARCOPLASMIC RETICULUM; SEX DIFFERENCE; SKELETAL MUSCLE; SMALL INTESTINE; SMOOTH MUSCLE FIBER; SUBMUCOSA; TEMPERATURE; TRACHEA; TRANSGENE; VAS DEFERENS; WILD TYPE;

EID: 79958134728     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/S1569-1993(11)60020-9     Document Type: Article

References (200)

1. Grubb BR, Boucher RC Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999, 79(1 Suppl):S193-S214.
2. Scholte BJ, Davidson DJ, Wilke M, De Jonge HR Animal models of cystic fibrosis. J Cyst Fibros 2004, 3(Suppl 2):183-190.
3. Guilbault C, Saeed Z, Downey GP, Radzioch D Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 2007, 36:1-7.
4. Rogers CS, Hao Y, Rokhlina T, et al. Production of CFTR-null and CFTR-ΔF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest 2008, 118:1571-1577.
5. Rogers CS, Abraham WM, Brogden KA, et al. The porcine lung as a potential model for cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 295:L240-L263.
6. Sun X, Yan Z, Yi Y, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest 2008, 118:1578-1583.
7. Meyerholz DK, Stoltz DA, Pezzulo AA, Welsh MJ Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. Am J Pathol 2010, 176:1377-1389.
8. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transi Med 2010, 2:29ra31.
9. French PJ, van Doorninck JH, Peters RH, et al. A ΔF508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo. J Clin Invest 1996, 98:1304-1312.
10. van Doorninck JH, French PJ, Verbeek E, et al. A mouse model for the cystic fibrosis ΔF508 mutation. EMBO J 1995, 14:4403-4411.
11. Delaney SJ, Alton EW, Smith SN, et al. Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations. EMBO J 1996, 15:955-963.
12. Hodges CA, Cotton CU, Palmert MR, Drumm ML Generation of a conditional null allele for Cftr in mice. Genesis 2008, 46:546-552.
13. + absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004, 10:487-493.
14. + channel-overexpressing mice. Am J Respir Crit Care Med 2008, 177:730-742.
15. + channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Exp Physiol 2009, 94:171-174.
16. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in βENaC-overexpressing mice. Am J Respir Crit Care Med 2008, 178:1245-1256.
17. Zhou Z, Duerr J, Johannesson B, et al. The βENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 2011, 10(Suppl2):172-182.
18. Reynaert I, Van Der Schueren B, Degeest G, et al. Morphological changes in the vas deferens and expression of the cystic fibrosis transmembrane conductance regulator (CFTR) in control, ΔF508 and knock-out CFTR mice during postnatal life. Mol Reprod Dev 2000, 55:125-135.
19. Durie PR, Kent G, Phillips MJ, Ackerley CA Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 2004, 164:1481-1493.
20. Wright JT, Kiefer CL, Hall KI, Grubb BR Abnormal enamel development in a cystic fibrosis transgenic mouse model. J Dent Res 1996, 75:966-973.
21. Chang HY, Mitzner W Sex differences in mouse models of asthma. Can J Physiol Pharmacol 2007, 85:1226-1235.
22. Kent G, Oliver M, Foskett JK, et al. Phenotypic abnormalities in long-term surviving cystic fibrosis mice. Pediatr Res 1996, 40:233-241.
23. Cottart CH, Bonvin E, Rey C, et al. Impact of nutrition on phenotype in CFTR-deficient mice. Pediatr Res 2007, 62:528-532.
24. Werner A, Bongers ME, Bijvelds MJ, de Jonge HR, Verkade HJ No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis. J Lipid Res 2004, 45:2277-2286.
25. Bijvelds MJ, Bronsveld I, Havinga R, Sinaasappel M, de Jonge HR, Verkade HJ Fat absorption in cystic fibrosis mice is impeded by defective lipolysis and post-lipolytic events. Am J Physiol Gastrointest Liver Physiol 2005, 288:G646-G653.
26. Ohlsson L, Hjelte L, Huhn M, et al. Expression of intestinal and lung alkaline sphingomyelinase and neutral ceramidase in cystic fibrosis F508del transgenic mice. J Pediatr Gastroenterol Nutr 2008, 47:547-554.
27. Rowntree RK, Harris A The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003, 67:471-485.
28. Thiagarajah JR, Verkman AS CFTR pharmacology and its role in intestinal fluid secretion. Curr Opin Pharmacol 2003, 3:594-599.
29. Valverde MA, Vazquez E, Muñoz FJ, et al. Murine CFTR channel and its role in regulatory volume decrease of small intestine crypts. Cell Physiol Biochem 2000, 10:321-328.
30. Venkatasubramanian J, Ao M, Rao MC Ion transport in the small intestine. Curr Opin Gastroenterol 2010, 26:123-128.
31. Kunzelmann K, Mall M Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002, 82:245-289.
32. Leverkoehne I, Holle H, Anton F, Gruber AD Differential expression of calcium-activated chloride channels (CLCA) gene family members in the small intestine of cystic fibrosis mouse models. Histochem Cell Biol 2006, 126:239-250.
33. Quinton PM Birth of Mucus. Am J Physiol Lung Cell Mol Physiol 2009, 298:L13-L14.
34. Garcia MA, Yang N, Quinton PM Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009, 119:2613-2622.
35. Malmberg EK, Noaksson KA, Phillipson M, et al. Increased levels of mucins in the cystic fibrosis mouse small intestine and modulator effects of the Mucl mucin expression. Am J Physiol Gastrointest Liver Physiol 2006, 291:G203-G210.
36. Charizopoulou N, Wilke M, Dorsch M, et al. Spontaneous rescue from cystic fibrosis in a mouse model. BMC Genet 2006, 7:18.
37. Wilke M, Bot A, Jorna H, Rensen S, De Jonge H Correction of the dF508-CFTR processing defect by low temperature incubation of mouse intestine. Pediatr Pulmonol Suppl 2003, 36:196.
38. Best JA, Quinton PM Salivary secretion assay for drug efficacy for cystic fibrosis in mice. Exp Physiol 2005, 90:189-193.
39. +/+ and Cflr-/-mice. J Cyst Fibros 2008, 7:128-133.
40. Catalán MA, Nakamoto T, Gonzalez-Begne M, et al. Cftr and ENaC ion channels mediate NaCl absorption in the mouse submandibular gland. J Physiol 2010, 588:713-724.
41. Jouret F, Bernard A, Hermans C, et al. Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis in mouse and human kidney. J Am Soc Nephrol 2007, 18:707-718.
42. Jouret F, Devuyst O CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch 2009, 457:1227-1236.
43. Feranchak AP Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004, 6:231-239.
44. Bodewes F, Wouthuizen Bakker M, Havinga R, Bijvelds M, de Jonge H, Verkade HJ Treatment with ursodeoxycholate, but not with cholic acid, increases bile flow independently of cystic fibrosis transmembrane conductance regulator in mice. Pediatr Pulmonol Suppl 2007, 30:376.
45. Peters RH, van Doorninck JH, French PJ, et al. Cystic fibrosis transmembrane conductance regulator mediates the cyclic adenosine monophosphate-induced fluid secretion but not the inhibition of résorption in mouse gallbladder epithelium. Hepatology 1997, 25:270-277.
46. Peters RH, French PJ, van Doorninck JH, et al. CFTR expression and mucin secretion in cultured mouse gallbladder epithelial cells. Am J Physiol Gastrointest Liver Physiol 1996, 271:1074-1083.
47. Divangahi M, Balghi H, Danialou G, et al. Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet 2009, 5:el000586.
48. Vandebrouck C, Melin P, Norez C, et al. Evidence that CFTR is expressed in rat trachéal smooth muscle cells and contributes to bronchodilation. Respir Res 2006, 7:113.
49. Robert R, Savineau JP, Norez C, Becq F, Guibert C Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries. Eur Respir J 2007, 30:857-864.
50. Michoud MC, Robert R, Hassan M, et al. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am J Respir Cell Mol Biol 2009, 40:217-222.
51. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006, 8:933-944.
52. Deriy LV, Gomez EA, Zhang G, et al. Diseasecausing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages. J Biol Chem 2009, 284:35926-35938.
53. Haggie PM, Verkman AS Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. Am J Physiol Lung Cell Mol Physiol 2009, 296:L859-L867.
54. Barriere H, Bagdany M, Bossard F, et al. Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. Mol Biol Cell 2009, 20:3125-3141.
55. Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and induced inflammation in ΔF508 cystic fibrosis mice. Respir Res 2006, 7:134.
56. Meyer M, Huaux F, Gavilanes X, et al. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009, 41:590-602.
57. -/- mice. Am J Respir Cell Mol Biol 2009, 40:295-304.
58. Gu Y, Harley IT, Henderson LB, et al. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature 2009, 458:1039-1042.
59. Kulka M, Gilchrist M, Duszyk M, Befus AD Expression and functional characterization of CFTR in mast cells. J Leukoc Biol 2002, 71:54-64.
60. Norkina O, Kaur S, Ziemer D, De Lisle RC Inflammation of the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2004, 286:G1032-G1041.
61. Xu Y, Tertilt C, Krause A, Quadri LE, Crystal RG, Worgall S Influence of the cystic fibrosis transmembrane conductance regulator on expression of lipid metabolism-related genes in dendritic cells. Respir Res 2009, 10:26.
62. Bonvin E, Le Rouzic P, Bernaudin JF, et al. Congenital tracheal malformation in cystic fibrosis transmembrane conductance regulator-deficient mice. J Physiol 2008, 586:3231-3243.
63. Liang H, Yang L, Ma T, Zhao Y Functional expression of cystic fibrosis transmembrane conductance regulator in mouse chondrocytes. Clin Exp Pharmacol Physiol 2010, 37:506-508.
64. 2+-regulated Cl secretory channel in mouse airways. J Biol Chem 2009, 284:14875-14880.
65. 2+ - dependent chloride transport. J Biol Chem 2009, 284:28698-28703.
66. Huang F, Rock JR, Harfe BD, et al. Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Nati Acad Sei U S A 2009, 106:21413-21418.
67. Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G Severe osteopenia in CFTR-null mice. Bone 2004, 35:595-603.
68. Pashuck TD, Franz SE, Altman MK, et al. Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation. Pediatr Res 2009, 65:311-316.
69. Hasten CK, Li W, Li A, Lafleur M, Henderson JE Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008, 177:309-315.
70. Bronckers A, Kalogeraki L, Jorna HJ, et al. The cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in maturation stage ameloblasts, odontoblasts and bone cells. Bone 2010, 46:1188-1196.
71. + driven lysosomal Cl accumulation. Science 2010, 328:1401-1403.
72. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001, 104:205-215.
73. Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int 2010, 86:1-7.
74. Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009, 10:134-142.
75. Hilliard TN, Zhu J, Farley R, et al. Nasal abnormalities in cystic fibrosis mice independent of infection and inflammation. Am J Respir Cell Mol Biol 2008, 39:19-25.
76. Grubb BR, Rogers TD, Kulaga HM, et al. Olfactory epithelia exhibit progressive functional and morphological defects in CF mice. Am J Physiol Cell Physiol 2007, 293:C574-C583.
77. De Jonge HR, Ballmann M, Veeze H, et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros 2004, 3(Suppl 2):159-163.
78. Boucher RC Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007, 13:231-240.
79. Elsaesser R, Paysan J Morituri te salutant? Olfactory signal transduction and the role of phosphoinositides. J Neurocytol 2005, 34:97-116.
80. Elsaesser R, Montani G, Tirindelli R, Paysan J Phosphatidyl-inositide signalling proteins in a novel class of sensory cells in the mammalian olfactory epithelium. Eur J Neurosci 2005, 21:2692-2700.
81. Ianowski JP, Choi JY, Wine JJ, Hanrahan JW Substance P stimulates CFTR-dependent fluid secretion by mouse trachéal submucosal glands. Pflugers Arch 2008, 457:529-537.
82. Ianowski JP, Choi JY, Wine JJ, Hanrahan JW Mucus secretion by single trachéal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice. J Physiol 2007, 580:301-314.
83. Grubb BR, Jones JH, Boucher RC Mucociliary transport determined by in vivo microdialysis in the airways of normal and CF mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L588-L595.
84. Zahm JM, Gaillard D, Dupuit F, et al. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am J Physiol Cell Physiol 1997, 272:C853-C859.
85. MacVinish LJ, Gill DR, Hyde SC, et al. Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTria110-CFTR2. J Physiol 1997, 499:677-687.
86. Schroeder BC, Cheng T, Jan YN, Jan LY Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008, 134:1019-1029.
87. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008, 322:590-594.
88. Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008, 455:1210-1215.
89. Rochelle LG, Li DC, Ye H, Lee E, Talbot CR, Boucher RC Distribution of ion transport mRNAs throughout murine nose and lung. Am J Physiol Lung Cell Mol Physiol 2000, 279:L 14-L 24.
90. Evans CM, Williams OW, Tuvim MJ, et al. Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol 2004, 31:382-394.
91. Park KS, Korfhagen TR, Bruno MD, et al. SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest 2007, 117:978-988.
92. Davis CW, Dickey BE Regulated airway goblet cell mucin secretion. Annu Rev Physiol 2008, 70:487-512.
93. Kulaksiz H, Schmid A, Honscheid M, Ramaswamy A, Cetin Y Clara cell impact in air-side activation of CFTR in small pulmonary airways. Proc Nati Acad Sci U S A 2002, 99:6796-6801.
94. Chinet TC, Gabriel SE, Penland CM, et al. CFTR-like chloride channels in non-ciliated bronchiolar epithelial (Clara) cells. Biochem Biophys Res Commun 1997, 230:470-475.
95. Tiddens HA, Donaldson SH, Rosenfeld M, Pare PD Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?. Pediatr Pulmonol 2010, 45:107-117.
96. Stick SM, Brennan S, Murray C, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009, 155:623-628.
97. Fang X, Song Y, Hirsch J, et al. Contribution of CFTR to apical-basolateral fluid transport in cultured human alveolar epithelial type II cells. Am J Physiol Lung Cell Mol Physiol 2006, 290:L242-L249.
98. Matthay MA, Robriquet L, Fang X Alveolar epithelium: role in lung fluid balance and acute lung injury. Proc Am Thorac Soc 2005, 2:206-213.
99. Lindert J, Perlman CE, Parthasarathi K, Bhattacharya J Chloride-dependent secretion of alveolar wall liquid determined by optical-sectioning microscopy. Am J Respir Cell Mol Biol 2007, 36:688-696.
100. Thomas GR, Costelloe EA, Lunn DP, et al. G551D cystic fibrosis mice exhibit abnormal regulation of inflammation in lungs and macrophages. J Immunol 2000, 164:3870-3877.
101. Kent G, Iles R, Bear CE, et al. Lung disease in mice with cystic fibrosis. J Clin Invest 1997, 100:3060-3069.
102. Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
103. Guilbault C, De Sanctis JB, Wojewodka G, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008, 38:47-56.
104. Gavilanes X, Huaux F, Meyer M, et al. Azithromycin fails to reduce increased expression of neutrophil-related cytokines in primary-cultured epithelial cells from cystic fibrosis mice. J Cyst Fibros 2009, 8:203-210.
105. van Heeckeren AM, Schluchter MD, Xue W, Davis PB Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice. Am J Respir Crit Care Med 2006, 173:288-296.
106. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 1997, 100:2810-2815.
107. Davidson DJ, Dorin JR, McLachlan G, et al. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nat Genet 1995, 9:351-357.
108. Stotland PK, Radzioch D, Stevenson MM Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis. Pediatr Pulmonol 2000, 30:413-424.
109. McMorran BJ, Palmer JS, Lunn DP, et al. G551D CF mice display an abnormal host response and have impaired clearance of Pseudomonas lung disease. Am J Physiol Lung Cell Mol Physiol 2001, 281:L740-L747.
110. Oceandy D, McMorran BJ, Smith SN, et al. Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Hum Mol Genet 2002, 11:1059-1067.
111. Bragonzi A, Paroni M, Nonis A, et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 2009, 180:138-145.
112. Moser C, Van Gennip M, Bjarnsholt T, et al. Novel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. APMIS 2009, 117:95-107.
113. van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 2004, 287:L944-L952.
114. van Heeckeren AM, Schluchter M, Xue L, et al. Nutritional effects on host response to lung infections with mucoid Pseudomonas aeruginosa in mice. Infect Immun 2004, 72:1479-1486.
115. Tsai WC, Hershenson MB, Zhou Y, Sajjan U Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. In-flamm Res 2009, 58:491-501.
116. Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol 2001, 166:7410-7418.
117. Coleman FT, Mueschenborn S, Meluleni G, et al. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Nati Acad Sci USA 2003, 100:1949-1954.
118. Reiniger N, Lee MM, Coleman FT, Ray C, Golan DE, Pier GB Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor. Infect Immun 2007, 75:1598-1608.
119. Raoust E, Balloy V, Garcia-Verdugo I, Touqui L, Ramphal R, Chignard M Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PloS One 2009, 4:e7259.
120. Morris AE, Liggitt HD, Hawn TR, Skerrett SJ Role of Toll-like receptor 5 in the innate immune response to acute P. aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1112-L1119.
121. Quinton PM Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008, 372:415-417.
122. Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. Am J Respir Cell Mol Biol 1998, 19:853-866.
123. Dif F, Wu YZ, Burgel PR, et al. Critical role of cytosolic phospholipase a2a in bronchial mucus hyper-secretion in CFTR-deficient mice. Eur Respir J 2010 Apr 22, [Epub ahead of print].
124. -/- mice. Proc Nati Acad Sci U S A 1999, 96:13995-14000.
125. Freedman SD, Shea JC, Blanco PG, Alvarez JG Fatty acids in cystic fibrosis. Curr Opin Pulm Med 2000, 6:530-532.
126. Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenie murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007, 292:G839-G848.
127. Guilbault C, Wojewodka G, Saeed Z, et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2009, 41:100-106.
128. Saeed Z, Guilbault C, De Sanctis JB, et al. Fenretinide prevents the development of osteoporosis in Cftr-KO mice. J Cyst Fibros 2008, 7:222-230.
129. Harmon GS, Dumlao DS, Ng DT, et al. Pharmacological correction of a defect in PPAR-? signaling ameliorates disease severity in Cftr-deficient mice. Nat Med 2010, 16:313-318.
130. Carvalho-Oliveira IM, Charro N, Aarbiou J, et al. Proteomic analysis of naphthalene-induced airway epithelial injury and repair in a cystic fibrosis mouse model. J Proteome Res 2009, 8:3606-3616.
131. Borot F, Vieu DL, Faure G, et al. Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells. PloS One 2009, 4:e7116.
132. Becker KA, Riethmuller J, Luth A, Döring G, Kleuser B, Gulbins E Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 2010, 42:716-724.
133. Riethmuller J, Anthonysamy J, Serra E, Schwab M, Döring G, Gulbins E Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. Cell Physiol Biochem 2009, 24:65-72.
134. Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O Pharmacological therapy for cystic fibrosis: From bench to bedside. J Cyst Fibros 2011, 10(Suppl 2):S129-S145.
135. Conese M, Ascenzioni F, Boyd AC, et al. Gene and cell therapy for cystic fibrosis: From bench to bedside. J Cyst Fibros 2011, 10(Suppl 2):129-145.
136. Sheppard DN, Welsh MJ Structure and function of the CFTR chloride channel. Physiol Rev 1999, 79(1 Suppl):S23-S45.
137. Lansdell KA, Delaney SJ, Lunn DP, Thomson SA, Sheppard DN, Wainwright BJ Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Cl channels expressed in mammalian cells. J Physiol 1998, 508:379-392.
138. Lansdell KA, Kidd JF, Delaney SJ, Wainwright BJ, Sheppard DN Regulation of murine cystic fibrosis transmembrane conductance regulator Cl channels expressed in Chinese hamster ovary cells. J Physiol 1998, 512:751-764.
139. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Nati Acad Sci U S A 2009, 106:18825-18830.
140. De Jonge H, Wilke M, Bot A, Jorna H, Wang W, Kirk K, et al. Differential response of mouse versus human CFTR to CFTR potentiators. Pediatr Pulmonol Suppl 2007, 30:208.
141. Scott-Ward TS, Cai Z, Dawson ES, et al. Chimeric constructs endow the human CFTR Cl channel with the gating behavior of murine CFTR. Proc Natl Acad Sci U S A 2007, 104:16365-16370.
142. Noël S, Wilke M, Bot AG, De Jonge HR, Becq F Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther 2008, 325:1016-1023.
143. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the a-glucosidase inhibitor miglustat. FEBS Lett 2006, 580:2081-2086.
144. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008, 177:506-515.
145. Robert R, Carlile GC, Liao J, et al. Correction of ΔPhe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol Pharmacol 2010, 77:922-930.
146. Meyer M, Huaux F, van den Brûle S, et al. Macrophage phenotype in ΔF508-CF mice: effect of azithromycin. Pediatr Pulmonol Suppl 2007, 30:256.
147. Nichols DP, Ziady AG, Shank SL, Eastman JF, Davis PB The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease. Am J Physiol Lung Cell Mol Physiol 2009, 297:L828-L836.
148. Stanke F, Ballmann M, Bronsveld I, et al. Diversity of the basic defect of homozygous CFTR mutation genotypes in humans. J Med Genet 2008, 45:47-54.
149. Collaco JM, Cutting GR Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 2008, 14:559-566.
150. Cutting GR Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005, 6:237-260.
151. Davies JC, Griesenbach U, Alton E Modifier genes in cystic fibrosis. Pediatr Pulmonol 2005, 39:383-391.
152. Gyömörey K, Rozmahel R, Bear CE Amelioration of intestinal disease severity in cystic fibrosis mice is associated with improved chloride secretory capacity. Pediatr Res 2000, 48:731-734.
153. TgH(neoim)Hgu cystic fibrosis mice. BMC Genet 2008, 9:28.
154. Haston CK, Corey M, Tsui LC Mapping of genetic factors influencing the weight of cystic fibrosis knockout mice. Mamm Genome 2002, 13:614-618.
155. Haston CK, McKerlie C, Newbigging S, Corey M, Rozmahel R, Tsui LC Detection of modifier loci influencing the lung phenotype of cystic fibrosis knockout mice. Mamm Genome 2002, 13:605-613.
156. Norkina O, De Lisle RC Potential genetic modifiers of the cystic fibrosis intestinal inflammatory phenotype on mouse chromosomes 1, 9, and 10. BMC Genet 2005, 6:29.
157. + channel β-subunit KCNE3 reveals an important role in intestinal and trachéal Cl transport. J Biol Chem 2010, 285:7165-7175.
158. Snouwaert JN, Brigman KK, Latour A, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992, 257:1083-1088.
159. Ratcliff R, Evans MJ, Cuthbert AW, et al. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 1993, 4:35-41.
160. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet 1996, 12:280-287.
161. Hasty P, O'Neal WK, Liu KQ, et al. Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene. Somat Cell Mol Genet 1995, 21:177-187.
162. Hazel WH. Phenotypes of gene-targeted mouse models of mild and severe cystic fibrosis. PhD Thesis 1999; University of Utah, USA.
163. O'Neal W, Hasty P, McCray P, et al. A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus. Hum Mol Genet 1993, 2:1561-1569.
164. Colledge WH, Abella BS, Southern KW, et al. Generation and characterization of a ΔF508 cystic fibrosis mouse model. Nat Genet 1995, 10:445-452.
165. Zeiher B, Eichwald E, Zabner J, et al. A mouse model for the ΔF508 allele of cystic fibrosis. J Clin Invest 1995, 96:2051-2064.
166. Dickinson P, Smith SN, Webb S, et al. The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mis-trafficking, normal survival and organ-specific bioelectrics. Hum Mol Genet 2002, 11:243-251.
167. Zhou L, Dey CR, Wert SE, DuVall MD, Frizzell RA, Whitsett JA Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 1994, 266:1705-1708.
168. Goncz KK, Kunzelmann K, Xu Z, Gruenert DC Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet 1998, 7:1913-1919.
169. Zielenski J Genotype and phenotype in cystic fibrosis. Respiration 2000, 67:117-133.
170. Lyczak JB, Cannon CL, Pier GB Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222.
171. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-KB translocation. Proc Nati Acad Sci U S A 2002, 99:6907-6912.
172. Tirkos S, Newbigging S, Nguyen V, et al. Expression of S100A8 correlates with inflammatory lung disease in congenie mice deficient of the cystic fibrosis transmembrane conductance regulator. Respir Res 2006, 7:51.
173. Chroneos ZC, Wert SE, Livingston JL, Hassett DJ, Whitsett JA Role of cystic fibrosis transmembrane conductance regulator in pulmonary clearance of Pseudomonas aeruginosa in vivo. J Immunol 2000, 165:3941-3950.
174. Finkbeiner WE Physiology and pathology of tracheobronchial glands. Respir Physiol 1999, 118:77-83.
175. Joo NS, Irokawa T, Robbins RC, Wine JJ Hyposecretion, not hyper-absorption, is the basic defect of cystic fibrosis airway glands. J Biol Chem 2006, 281:7392-7398.
176. Wilson JW, Robertson CF Angiogenesis in paediatric airway disease. Paediatr Respir Rev 2002, 3:219-229.
177. de Jong PA, Ottink MD, Robben SG, et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004, 231:434-439.
178. Guilbault C, Novak JP, Martin P, et al. Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. Physiol Genomics 2006, 25:179-193.
179. Winfield RD, Beierle EA Pediatric surgical issues in meconium disease and cystic fibrosis. Surg Clin North Am 2006, 86:317-327. viii-ix.
180. Borowitz D, Durie PR, Clarke LL, et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 2005, 41:273-285.
181. Walker NM, Simpson JE, Levitt RC, Boyle KT, Clarke LL Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. J Pharmacol Exp Ther 2006, 317:275-283.
182. Rosenberg LA, Schluchter MD, Parlow AF, Drumm ML Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res 2006, 59:191-195.
183. Colombo C Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007, 13:529-536.
184. Moyer K, Balistreri W Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2009, 25:272-278.
185. Williams SM, Goodman R, Thomson A, McHugh K, Lindsell DR Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002, 57:365-370.
186. -/- mice. J Cell Physiol 2004, 200:235-244.
187. -/- mice. J Pediatr Gastroenterol Nutr 2006, 42:275-281.
188. Yahiaoui Y, Jablonski M, Hubert D, et al. Renal involvement in cystic fibrosis: diseases spectrum and clinical relevance. Clin J Am Soc Nephrol 2009, 4:921-928.
189. tm2cam mice. J Physiol 2000, 526:27-34.
190. Lu M, Leng Q, Egan ME, et al. CFTR is required for PKA-regulated ATP sensitivity of Kirl. 1 potassium channels in mouse kidney. J Clin Invest 2006, 116:797-807.
191. Curtis CM, Martin LC, Higgins CF, et al. Restoration by intratracheal gene transfer of bicarbonate secretion in cystic fibrosis mouse gallbladder. Am J Physiol Gastrointest Liver Physiol 1998, 274:G1053-G1060.
192. King LJ, Scurr ED, Muragan N, Williams SG, Westaby D, Healy JC Hepatobiliary and pancreatic manifestations of cystic fibrosis: MR imaging appearances. Radiographies 2000, 20:767-777.
193. Steward MC, Ishiguro H, Case RM Mechanisms of bicarbonate secretion in the pancreatic duct. Annu Rev Physiol 2005, 67:377-409.
194. Pascua P, Garcia M, Fernandez-Salazar MP, et al. Ducts isolated from the pancreas of CFTR-null mice secrete fluid. Pflugers Arch 2009, 459:203-214.
195. Ferguson DB The flow rate and composition of human labial gland saliva. Arch Oral Biol 1999, 44(Suppl 1):S11-S14.
196. Sato K, Cavallin S, Sato KT, Sato F Secretion of ions and pharmacological responsiveness in the mouse paw sweat gland. Clin Sci (Lond) 1994, 86:133-139.
197. + absorption analyzed using an electrokinetic model. Invest Ophthalmol Vis Sci 2006, 47:306-316.
198. Zaidi TS, Lyczak J, Preston M, Pier GB Cystic fibrosis transmembrane conductance regulator-mediated corneal epithelial cell ingestion of Pseudomonas aeruginosa is a key component in the pathogenesis of experimental murine keratitis. Infect Immun 1999, 67:1481-1492.
199. Levin MH, Verkman AS Aquaporins and CFTR in ocular epithelial fluid transport. J Membr Biol 2006, 210:105-115.
200. Pan J, Luk C, Kent G, Cutz E, Yeger H Pulmonary neuroendocrine cells, airway innervation and smooth muscle are altered in Cftr null mice. Am J Respir Cell Mol Biol 2006, 35:320-326.